# Immune Checkpoint Inhibitors Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC

> **NCT06132698** · PHASE2 · RECRUITING · sponsor: **West China Hospital** · enrollment: 17 (estimated)

## Conditions studied

- NSCLC Associated With Leptomeningeal Metastases

## Interventions

- **DRUG:** Tislelizumab or pembrolizumab, pemetrexed

## Key facts

- **NCT ID:** NCT06132698
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-30
- **Primary completion:** 2026-05-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 17 (ESTIMATED)
- **Last updated:** 2026-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06132698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06132698, "Immune Checkpoint Inhibitors Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT06132698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*